These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25952465)

  • 1. Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.
    Xie X; Wang L; Yang W; Yu R; Li Q; Pang X
    Invest New Drugs; 2015 Aug; 33(4):810-5. PubMed ID: 25952465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of DNA vaccination against botulinum neurotoxin serotype A by co-administration of plasmids encoding DC-stimulating Flt3L and MIP-3α cytokines.
    Xu Q; Zhu YF; Wang HC; Gong ZW; Yu YZ
    Biologicals; 2016 Sep; 44(5):441-7. PubMed ID: 27430905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells.
    Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT
    Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.
    Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW
    Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant.
    Li N; Yu YZ; Yu WY; Sun ZW
    Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):211-9. PubMed ID: 21284488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency.
    Guo JH; Fan MW; Sun JH; Jia R
    Int Immunopharmacol; 2009 Jul; 9(7-8):925-30. PubMed ID: 19348967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A.
    Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY
    Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A.
    Yu YZ; Ma Y; Chen YX; Gong ZW; Wang S; Yu WY; Sun ZW
    Hum Vaccin; 2011 Oct; 7(10):1090-5. PubMed ID: 21941093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
    Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z
    Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mouse macrophage-derived chemokine as an adjuvant enhances the protective effect of P6 protein vaccine of nontypeable Haemophilus influenzae].
    Han X; Wang C; Qiao H; Zhang Y; Chang Y; Zhang Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Sep; 30(9):913-6. PubMed ID: 25200152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune effects of four coxsackievirus B3 VP1 DNA fusion vaccines in mice].
    Liu GX; Lan JM; Chuai X; Gao ZY; Jin YH; Zhang YH; Xie LX; Yin CF; Wang YX
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Feb; 26(2):103-6. PubMed ID: 20230664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen.
    Yu YZ; Sun ZW; Wang S; Yu WY
    Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):812-7. PubMed ID: 18051857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of macrophage-derived chemokine (MDC, CCL22) production.
    Yamashita U; Kuroda E
    Crit Rev Immunol; 2002; 22(2):105-14. PubMed ID: 12433129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of immunoglobulin E specific to the major food allergen and chemokine (C-C motif) ligand (CCL)17/thymus and activation regulated chemokine and CCL22/macrophage-derived chemokine in infantile atopic dermatitis on Ishigaki Island.
    Esaki H; Takeuchi S; Furusyo N; Yamamura K; Hayashida S; Tsuji G; Takemura M; Hayashi J; Furue M
    J Dermatol; 2016 Nov; 43(11):1278-1282. PubMed ID: 27028543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CCL22/macrophage-derived chemokine in allergic rhinitis.
    Yanai M; Sato K; Aoki N; Takiyama Y; Oikawa K; Kobayashi H; Kimura S; Harabuchi Y; Tateno M
    Clin Immunol; 2007 Dec; 125(3):291-8. PubMed ID: 17911044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDC/CCL22 intrathecal levels in patients with multiple sclerosis.
    Galimberti D; Fenoglio C; Comi C; Scalabrini D; De Riz M; Leone M; Venturelli E; Cortini F; Piola M; Monaco F; Bresolin N; Scarpini E
    Mult Scler; 2008 May; 14(4):547-9. PubMed ID: 18208895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage-Derived Chemokine MDC/CCL22: An Ambiguous Finding in COVID-19.
    Korobova ZR; Arsentieva NA; Totolian AA
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity.
    Biragyn A; Tani K; Grimm MC; Weeks S; Kwak LW
    Nat Biotechnol; 1999 Mar; 17(3):253-8. PubMed ID: 10096292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.